Published in JCI Insight on July 06, 2017
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52
Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods (2009) 18.51
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes (2005) 5.22
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics (2013) 4.73
Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun (2013) 4.22
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology (2015) 3.17
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology (2015) 3.12
Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech (2011) 2.97
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (2015) 2.81
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology (2016) 2.25
Clinical evidence for the regression of liver fibrosis. J Hepatol (2012) 2.16
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2012) 2.08
Disease signatures are robust across tissues and experiments. Mol Syst Biol (2009) 1.93
Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. Cell Host Microbe (2015) 1.83
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology (2013) 1.78
Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.75
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol (2013) 1.75
Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J (1992) 1.72
Pathobiology of liver fibrosis: a translational success story. Gut (2015) 1.72
Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (2015) 1.68
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One (2015) 1.68
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology (2009) 1.67
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J Hepatol (2013) 1.55
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res (2016) 1.52
NAFLD: a multisystem disease. J Hepatol (2015) 1.51
Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol (2010) 1.49
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
Differential gene expression in periportal and perivenous mouse hepatocytes. FEBS J (2006) 1.41
Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol (1998) 1.39
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol (2014) 1.37
Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol (2003) 1.35
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.33
Glucocorticoids promote chondrogenic differentiation of adult human mesenchymal stem cells by enhancing expression of cartilage extracellular matrix genes. Stem Cells (2006) 1.26
MiR-122 in hepatic function and liver diseases. Protein Cell (2012) 1.24
The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology (2012) 1.21
Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J Biol Chem (2013) 1.18
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One (2012) 1.13
Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One (2010) 1.13
Dermatopontin interacts with transforming growth factor beta and enhances its biological activity. Biochem J (1999) 1.12
Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci (Landmark Ed) (2012) 1.12
Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. J Invest Dermatol (2002) 1.10
Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 1.07
Dermatopontin, a novel player in the biology of the extracellular matrix. Connect Tissue Res (2006) 1.04
Regulation of hepatic six transmembrane epithelial antigen of prostate 4 (STEAP4) expression by STAT3 and CCAAT/enhancer-binding protein alpha. J Biol Chem (2010) 0.99
Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One (2012) 0.97
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2015) 0.97
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol (2015) 0.95
Extracellular matrix 22-kDa protein interacts with decorin core protein and is expressed in cutaneous fibrosis. J Biochem (1996) 0.95
Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound. Adv Wound Care (New Rochelle) (2016) 0.94
The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol (2015) 0.94
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2014) 0.93
PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res (2002) 0.93
Cell-type-resolved quantitative proteomics of murine liver. Cell Metab (2014) 0.93
DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by α3β1 integrin-Rho GTPase signaling. Oncotarget (2014) 0.91
Instructive roles of extracellular matrix on autophagy. Am J Pathol (2014) 0.90
Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer (2013) 0.90
Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest (2012) 0.89
Undulin RNA and protein expression in normal and fibrotic human liver. Hepatology (1994) 0.89
Dermatopontin interacts with fibronectin, promotes fibronectin fibril formation, and enhances cell adhesion. J Biol Chem (2011) 0.89
Sinusoidal communication in liver fibrosis and regeneration. J Hepatol (2016) 0.88
Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne) (2014) 0.88
Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans. Gastroenterology (2015) 0.88
Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology (2015) 0.87
The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology (2014) 0.85
Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways. Cell Rep (2015) 0.84
Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis. Am J Physiol Cell Physiol (2015) 0.84
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol (2015) 0.83
Histamine receptor H1 and dermatopontin: new downstream targets of the vitamin D receptor. J Bone Miner Res (2007) 0.82
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology (2016) 0.81
Extracellular matrix and liver disease. Antioxid Redox Signal (2014) 0.80
Dermatopontin regulates fibrin formation and its biological activity. J Invest Dermatol (2013) 0.79
Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. Hepatol Res (2008) 0.79
Identification of fibronectin binding sites in dermatopontin and their biological function. J Dermatol Sci (2014) 0.76
Functional peptide of dermatopontin produces fibrinogen fibrils and modifies its biological activity. J Dermatol Sci (2014) 0.76
A Cell-type-resolved Liver Proteome. Mol Cell Proteomics (2016) 0.75
Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest (2017) 0.75